The EGF-LIKE domain of thrombospondin-4 is a key determinant in the development of pain states due to increased excitatory synaptogenesis

Received for publication, April 29, 2018, and in revised form, September 5, 2018 Published, Papers in Press, September 7, 2018, DOI 10.1074/jbc.RA118.003591

John Francisco Park, Yanhui Peter Yu, Nian Gong, Van Nancy Trinh, and Z. David Luo

From the Departments of Pharmacology and Anesthesiology and Perioperative Care, University of California, Irvine, California 92697

Edited by Mike Shipston

Up-regulation of thrombospondin-4 (TSP4) or voltage-gated calcium channel subunit \( \alpha_2 \delta_1 \) (Cav\( \alpha_2 \delta_1 \)) proteins in the spinal cord contributes to neuropathic pain development through an unidentified mechanism. We have previously shown that TSP4 interacts with Cav\( \alpha_2 \delta_1 \) to promote excitatory synaptogenesis and the development of chronic pain states. However, the TSP4 determinants responsible for these changes are not known. Here, we tested the hypothesis that the Cav\( \alpha_2 \delta_1 \)-binding domains of TSP4 are synaptogenic and pronociceptive. We mapped the major Cav\( \alpha_2 \delta_1 \)-binding domains of TSP4 within the coiled-coil and epidermal growth factor (EGF)-like domains in vitro. Intrathecal injection of TSP4 fragment proteins containing the EGF-like domain (EGF-LIKE) into naïve rodents was sufficient for inducing behavioral hypersensitivity similar to that produced by an equal molar dose of full-length TSP4. Gabapentin, a drug that binds to Cav\( \alpha_2 \delta_1 \), blocked EGF-LIKE–induced behavioral hypersensitivity in a dose-dependent manner, supporting the notion that EGF-LIKE interacts with Cav\( \alpha_2 \delta_1 \) and thereby mediates behavioral hypersensitivity. This notion was further supported by our findings that a peptide within EGF-LIKE (EGFD355–369) could block TSP4- or Cav\( \alpha_2 \delta_1 \)-induced behavioral hypersensitivity after intrathecal injections. Furthermore, only TSP4 proteins that contained EGF-LIKE could promote excitatory synaptogenesis between sensory and spinal cord neurons, which could be blocked by peptide EGFD355–369. Together, these findings indicate that EGF-LIKE is the molecular determinant that mediates aberrant excitatory synaptogenesis and chronic pain development. Blocking interactions between EGF-LIKE and Cav\( \alpha_2 \delta_1 \) could be an alternative approach in designing target-specific pain medications.

Neuropathic pain, or pain states derived from injuries to the peripheral or central nervous systems, includes spontaneous pain and evoked pain such as tactile allodynia (exaggerated response to otherwise innocuous tactile stimuli) and hyperalgesia (exaggerated pain sensations to mildly noxious stimuli) (1, 2). Most current pain medications are not efficacious against neuropathic pain and are often associated with intolerable side effects. Identifying new targets and pathways involved in neuropathic pain processing is an unmet medical need that can provide mechanistic insights leading to development of target-specific pain medication. In the search for new targets/pathways critical in pain state development, our group and others have reported that peripheral nerve injury induces a parallel up-regulation of the astrocyte-secreted extracellular matrix protein thrombospondin-4 (TSP4) (3) and voltage-gated calcium channel \( \alpha_2 \delta_1 \) subunit (Cav\( \alpha_2 \delta_1 \)) in the dorsal root ganglia (DRG) and dorsal spinal cord that correlates with the development of behavioral hypersensitivities (3–9).

TSPs are large oligomeric, multidomain, extracellular matrix proteins that mediate cell/cell and cell/matrix interactions through binding to other extracellular matrix proteins, membrane proteins, and cytokines (10, 11). The TSP family consists of two subfamilies, subgroup A (TSP1 and -2) and subgroup B (TSP3–5), which are distinguished by their oligomerization states and domain structures. TSP4 has been shown to play a role in the development of neuropathic pain states. Intrathecal injection of TSP4 recombinant proteins into naïve rodent animals causes exaggerated presynaptic excitatory input into dorsal spinal cord and behavioral hypersensitivity (9, 12). TSP4 blockade by intrathecal treatments with antisense oligodeoxynucleotides, antibodies, or genetic ablation of the TSP4 gene reverses or prevents behavioral hypersensitivity induced by injuries to the peripheral and central nervous systems or intrathecal injection of TSP4 recombinant proteins (9, 13, 14).

Interestingly, TSP4-induced spinal cord neuron sensitization and behavioral hypersensitivity can be blocked by gabapentin, a gabapentinoid drug that binds to Cav\( \alpha_2 \delta_1 \) (15, 16), suggesting that TSP4 induces spinal cord sensitization.

The abbreviations used are: TSP4, thrombospondin-4; EGF, epidermal growth factor; Cav\( \alpha_2 \delta_1 \), voltage-gated calcium channel; EGF-LIKE, EGF-like domain; DRG, dorsal root ganglia; Tg, transgenic; Hek, human embryonic kidney; i.t., intrathecal; WVF-A, von Willebrand factor A; NMDA, N-methyl-D-aspartate; DMEM, Dulbecco’s modified Eagle’s medium; Bis-Tris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; HRP, horseradish peroxidase; PWT, paw withdrawal threshold; VGlut2, vesicular glutamate transporter 2; PSD95, postsynaptic density protein 95; MAP2, microtubule-associated protein 2; ANOVA, analysis of variance.

This work supported in part by National Institutes of Health Grants DE021847 and NS064341 (to Z. D. L.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

1 Recipient of Pre-Doctoral Fellowship in Pharmacology/Toxicology PRMAF-52427 from the Pharmaceutical Research and Manufacturers of America Foundation.

2 To whom correspondence should be addressed: Dept. of Anesthesiology and Perioperative Care, University of California Irvine, Gillespie Bldg., Rm. 3113, 837 Health Sciences Rd., Irvine, CA 92697. Tel.: 949-824-7469; Fax: 949-824-7447; E-mail: zluo@uci.edu.
and behavioral hypersensitivity through its interactions with Ca\textsubscript{\alpha,\delta\_1} (12). Multiple lines of evidence also support this notion. Transgenic (TG) mice overexpressing Ca\textsubscript{\alpha,\delta\_1} in neuronal tissues exhibit dorsal horn neuron hyperexcitability (17–19) and behavioral hypersensitivity (20) without nerve injury that can be blocked by TSP4 antibodies or viral or genetic ablation of TSP4 (12). In addition, genetic ablation of Ca\textsubscript{\alpha,\delta\_1} or gabapentin treatment can block TSP4-induced spinal neuron sensitization and behavioral hypersensitivity (12, 21). Furthermore, TSP4 proteins interact with Ca\textsubscript{\alpha,\delta\_1} to promote excitatory synaptogenesis in dorsal spinal cord that can be blocked by gabapentin or genetic ablation of Ca\textsubscript{\alpha,\delta\_1} (12, 21). All these findings support that activation of a TSP4/Ca\textsubscript{\alpha,\delta\_1} pathway is critical in promoting central sensitization and pain states, at least partially through aberrant excitatory synaptogenesis (12, 21). Thus, blocking the activated TSP4/Ca\textsubscript{\alpha,\delta\_1} pathway could be an alternative approach in developing specific interventions for pain relief. However, both TSP4 and Ca\textsubscript{\alpha,\delta\_1} are large proteins, so it is difficult to design small molecules or other drugs to block their interactions for pain relief without knowing the Ca\textsubscript{\alpha,\delta\_1}-interacting and nociceptive domains of TSP4. Accordingly, we tested the hypothesis in this study that the Ca\textsubscript{\alpha,\delta\_1}-interacting domains of TSP4 play a critical role in promoting behavioral hypersensitivity, at least partially through enhancing spinal cord excitatory synaptogenesis.

Figure 1. Identification of Ca\textsubscript{\alpha,\delta\_1}-binding domains of TSP4. A, top, domain structure of full-length TSP4 and recombinant TSP4 truncation proteins. Shown are the N-terminal domain (blue), coiled-coil oligomerization domain (gray), four type II EGF-like domain repeats (orange), seven type-3 calcium-binding repeats (yellow), and the C-terminal domain (green). Bottom, representative Western blots under reducing conditions showing each purified recombinant TSP4 truncated protein detected by anti-His antibodies. The approximate molecular mass (kDa) is shown on the left. B, binding of FLAG-Ca\textsubscript{\alpha,\delta\_1} to immobilized TSP4 or truncated TSP4 proteins at equal molar concentrations to TSP4 (80 μg/ml) in an ELISA-based ligand binding assay. Data presented in the box-and-whisker plot are from six to nine independent determinations; ****, p < 0.0001 compared with full-length TSP4 by one-way ANOVA with Bonferroni’s multiple comparisons test. C, summary of normalized binding of Ca\textsubscript{\alpha,\delta\_1} lysates to 15-mer peptides (overlapping by 12 amino acids) encompassing the entire TSP4 amino acid sequence. Summarized data are normalized to peptide 78.

Results

Mapping Ca\textsubscript{\alpha,\delta\_1}-binding motifs of TSP4

We have shown previously that injury-induced spinal TSP4 contributes to the development of neuropathic pain states (9) through a direct interaction with Ca\textsubscript{\alpha,\delta\_1} proteins (12). To identify the TSP4-binding domain to Ca\textsubscript{\alpha,\delta\_1}, we created five recombinant truncation constructs of TSP4: the N-terminal domain deletion construct (ND) encoding the EGF-LIKE domains, type-3 calcium-binding domain, and C-terminal domain; the EGF-like domain construct (EGF-LIKE) encoding EGF-LIKE; the C-terminal domain construct (CD) encoding the type-3 calcium-binding domain and C-terminal domain; the N-terminal domain alone construct (NT); and the N-terminal domain plus the coiled-coil domain construct (NT+CC) (Fig. 1A, top). TSP4 mutant proteins from these constructs were expressed in the human embryonic kidney (HEK) cell line 293-EBNA and purified through His-tag columns (Fig. 1A, bottom). Binding of the recombinant TSP4 proteins to recombinant Ca\textsubscript{\alpha,\delta\_1} proteins was tested in an ELISA-based ligand binding assay. Our data indicated that domain proteins containing EGF-LIKE (ND and EGF-LIKE) and coiled-coil domain of TSP4 bound to Ca\textsubscript{\alpha,\delta\_1} with a similar or over 70% capacity as the full-length TSP4, whereas binding of domain proteins containing the N-terminal domain, type-3 calcium-binding domain, and C-terminal domain to Ca\textsubscript{\alpha,\delta\_1} was about 35% of
that observed for full-length TSP4 (Fig. 1B). Thus, the coiled-coil and EGF-LIKE domains of TSP4 likely contained the major \(\text{Ca}_{\alpha_2}\delta_1\)-binding sites.

We further examined the \(\text{Ca}_{\alpha_2}\delta_1\)-binding motifs of TSP4 with SPOT peptide array analysis by measuring binding of recombinant \(\text{Ca}_{\alpha_2}\delta_1\) purified from transfected HEK 293 cells to immobilized overlapping 15-mer peptides that covered the entire length of TSP4. Similar to data from protein binding assays, TSP4 linear peptides with high affinity to \(\text{Ca}_{\alpha_2}\delta_1\) were clustered in the coiled-coil and EGF-LIKE domains but not in the type-3 calcium-binding domain (Fig. 1C). A few peptides from the N-terminal and C-terminal domains also bound to \(\text{Ca}_{\alpha_2}\delta_1\), which might contribute to the low binding affinity to \(\text{Ca}_{\alpha_2}\delta_1\) observed from the NT and CD truncated proteins (Fig. 1, B and C).

**EGF-LIKE domain of TSP4 is pronociceptive**

Previous findings have shown that increased spinal TSP4 protein alone is sufficient to induce tactile allodynia and thermal hyperalgesia (9) through interactions with \(\text{Ca}_{\alpha_2}\delta_1\) (12). To identify the pronociceptive domain of TSP4, we injected the recombinant truncated TSP4 proteins into L5/6 spinal region of naïve adult rats and tested their hind paw sensitivity to mechanical and thermal stimuli. Intrathecal (i.t.) injection of EGF-LIKE–containing proteins (EGF-like and ND), at an equal molar dose to the pronociceptive dose of full-length TSP4 (45 \(\mu\text{g/rat}\)) (9), induced a reduction in paw withdrawal thresholds to von Frey filaments (tactile allodynia) (Fig. 2A) and paw withdrawal latency to radiant heat (thermal hyperalgesia) (Fig. 2B). The pronociceptive effects of EGF-LIKE–containing proteins started within 2 days and lasted for about 1 week post-i.t. injection, similar to that induced by full-length TSP4 proteins (9). In contrast, neither lowering the dose of EGF-LIKE proteins to a molar dose (5 \(\mu\text{g/rat}\)) equivalent to the sub-pronociceptive dose of full-length TSP4 (20 \(\mu\text{g/rat}\)) (Fig. 3A) (9) nor injecting...
recombinant truncated proteins without EGF-LIKE (CD, NT, and NT + CC) at a molar dose equivalent to the pronociceptive dose of full-length TSP4 (45 μg/rat) (Fig. 2) cause behavioral hypersensitivity. Similar to its anti-nociceptive effects post-TSP4 injection (12), Ca\(_{\alpha_2\delta_1}\) ligand gabapentin could dose-dependently reverse tactile allodynia induced by EGF-LIKE within an hour post-i.t. injection (Fig. 3, A and B). Together, these findings support that EGF-LIKE is the functional determinant of TSP4’s pronociceptive effects, and its interaction with the Ca\(_{\alpha_2\delta_1}\) proteins is likely required for TSP4’s pronociceptive effects.

**Effects of intrathecal injection of peptide EGFD355–369 on behavioral hypersensitivities induced by elevated TSP4 and/or Ca\(_{\alpha_2\delta_1}\)**

Because EGF-LIKE is the pronociceptive domain, we tested whether a peptide within the EGF-LIKE domain of TSP4 could interfere with behavioral hypersensitivity induced by increased TSP4 and/or Ca\(_{\alpha_2\delta_1}\) in vivo. Based on the SPOT peptide array analysis (Fig. 1C), we identified peptide EGFD355–369 within EGF-LIKE as highly conserved in rodents and having high binding affinity to Ca\(_{\alpha_2\delta_1}\). This peptide was synthesized and injected i.t. into the L5/6 spinal region of TSP4-injected rats when the animals had severe allodynia (day 3 or 4 after bolus TSP4 injection). A blind behavioral sensitivity test to von Frey filament stimulation was performed daily after the TSP4 injection before and every 2 h for up to 6 h after each peptide injection. Our data indicated that peptide EGFD355–369, but not its scrambled peptide control, blocked TSP4-induced tactile allodynia dose-dependently. This effect lasted for >6 h (Fig. 4A). Bolus injection of peptide EGFD355–369 alone into naïve rats at the highest dose tested (2.1 nmol/rat) did not cause significant changes in baseline behavioral sensitivity acutely (Fig. 4A) or chronically (Fig. 4B). These data support that peptide EGFD355–369 can block TSP4-induced tactile allodynia.

To confirm that the anti-nociceptive effects of peptide EGFD355–369 were mediated by interfering with the activation of a pathway due to TSP4/Ca\(_{\alpha_2\delta_1}\) interactions, we examined its effect on mechanical allodynia in a Ca\(_{\alpha_2\delta_1}\) TG mouse line with increased neuronal Ca\(_{\alpha_2\delta_1}\) overexpression (20). This model has been shown to enhance excitatory synaptic transmission in dorsal spinal cord that contributes to behavioral hypersensitivity (12, 17–20). Our data indicated that intrathecal injection of the effective dose (0.047 nmol/mouse) of peptide EGFD355–369, but not its scrambled peptide, could reverse allodynia in the Ca\(_{\alpha_2\delta_1}\) TG mice with an onset time of 2 h and a duration <6 h (Fig. 5). These data indicate that peptide EGFD355–369 can attenuate tactile allodynia induced by Ca\(_{\alpha_2\delta_1}\), most likely through its interactions with TSP4 (12).

**EGF-LIKE domain of TSP4 is synaptogenic**

To determine whether EGF-LIKE induces excitatory synaptogenesis that may underlie its nociceptive effects, we examined the synaptogenic effects of TSP4 domain proteins derived from the constructs shown in Fig. 1 in cocultures of DRG and spinal cord neurons. Treatments of cocultures with an equal molar concentration of recombinant proteins containing EGF-LIKE, such as that encoded by full-length TSP4, ND, and EGF-LIKE domain constructs, resulted in significant increases of excitatory synapse numbers compared with control (PBS treatment). There was no significant difference in synaptic numbers among treatments with these EGF-LIKE–containing proteins (Fig. 6). In contrast, treatments with proteins lacking EGF-LIKE, such as those encoded by the CD and NT+CC constructs, did not induce significant excitatory synapse formation compared with control (Fig. 6). These data indicate that EGF-LIKE is synaptogenic and promotes excitatory synapse formation between sensory neurons and spinal cord neurons.
processes, here we have identified the Cavapse formation induced by EGF-LIKE (not the scrambled control peptide, blocked the increase of syn- 
trol. Concurrent treatments with peptide EGFD355–369, but 
significant increase of excitatory synapses compared with the con- 
effects of EGF-LIKE.

Figure 5. Cavα2δ1-induced tactile allodynia could be attenuated by intrathecal injection of peptide EGFD355–369. A bolus i.t. injection of pep- tide EGFD355–369 or its scrambled control peptide (0.047 nmol/mouse) at an 
equal molar dose to the pronociceptive dose of TSP4 (5 μg/mouse) was adminis- tered to Cavα2δ1-overexpressing TG mice and their age- and sex-
matched WT littermates at time 0 followed by a blind behavioral test for PWTs 
to von Frey filament stimuli at 2, 4, and 6 h after bolus peptide treatments. 
Data presented are the means from 10 mice in each group with error bars 
representing S.E. **, p < 0.01; ***, p < 0.001 compared with pretreatment 
level by repeated measures one-way ANOVA with Bonferroni’s multiple compar- 
isons test.

**EGFD355–369 can block synaptogenesis induced by EGF-LIKE domain of TSP4**

To determine whether peptide EGFD355–369 could block 
excitatory synaptogenesis induced by EGF-LIKE, we examined 
the effects of peptide EGFD355–369 on excitatory synaptogenesis 
induced by EGF-LIKE in the cocultures. Similar to that 
shown in Fig. 6, treatments with EGF-LIKE resulted in a signif- 
icant increase of excitatory synapses compared with the con- 
tral. Concurrent treatments with peptide EGFD355–369, but 
not the scrambled control peptide, blocked the increase of syn- 
apse formation induced by EGF-LIKE (Fig. 7). These data sup- 
port that peptide EGFD355–369 can block the synaptogenic 
effects of EGF-LIKE.

**Discussion**

Peripheral nerve injury induces concurrent up-regulation of 
TSP4 and Cavα2δ1 in dorsal spinal cord (5, 9), and TSP4/Cavα2δ1 
interactions promotes excitatory synaptogenesis and 
chronic pain states (12). To gain molecular insight into these 
processes, here we have identified the Cavα2δ1-binding motifs of TSP4 and that EGF-LIKE is synaptogenic and nocic- 
ceptive. Administration of gabapentin blocks behavioral hy- 
persensitivity induced by EGF-LIKE. Administration of the 
EGFD355–369 peptide from within the EGF-LIKE motif blocks 
excitatory synaptogenesis induced by EGF-LIKE as well as tact- icle allodynia induced by elevated TSP4 or Cavα2δ1. Together, 
our findings support that EGF-LIKE is a functional determinant 
in promoting aberrant excitatory synaptogenesis and sensory 
hypersensitivity resulting from activation of a TSP4/Cavα2δ1 
pathway.

**Multidomain interactions between TSP4 and Cavα2δ1**

We used SPOT peptide synthesis method and an ELISA-
based binding assay to map the linear and discontinuous bind- 
ing sites of TSP4 to Cavα2δ1. Our data indicate that most TSP4 
linear peptides with relatively high binding affinity to Cavα2δ1 
are located within the coiled-coil and EGF-LIKE domains, but 
not the type-3 calcium-binding domain, of TSP4. However, a 
few discontinuous peptides from the TSP4 N-terminal and 
C-terminal domains also bind to Cavα2δ1 with high affinity and 
may be responsible for the low-affinity binding of TSP4 trunc- 
ted N- or C-terminal domain proteins to Cavα2δ1. Thus, the 
binding interaction between TSP4 and Cavα2δ1 is likely medi- 
ated through multidomain interactions, which may lead to 
subsequent conformational changes of the binding proteins. 
Recent data from a cotransfection study suggest that TSP4/Cav 
α2δ1 interactions occur intracellularly (22). Therefore, the 
exact location of TSP4/Cavα2δ1 interactions in vivo remains to 
be established.

**Specific interactions between the TSP4 EGF-LIKE domain and Cavα2δ1 are critical in TSP4-induced behavioral hypersensitivity**

Functionally, we show that only truncated TSP4 proteins 
containing EGF-LIKE promote behavioral hypersensitivities 
like full-length TSP4 proteins. Intriguingly, those containing 
the N-terminal, coiled-coil, calcium-binding, and C-terminal 
domains fail to elicit behavioral hypersensitivity even though 
some of these proteins, such as that encoded by the NT+CC 
construct, have similar Cavα2δ1 binding affinity as full-length 
TSP4. Thus, multidomain-binding interactions between TSP4 
and Cavα2δ1 may facilitate specific interactions between EGF- 
LIKE and Cavα2δ1, which are critical in mediating behavioral 
hypersensitivity. It is reported that EGF-LIKE interacts with 
von Willebrand factor A (VWF-A) domain of Cavα2δ1 in pro- 
moting central nervous system excitatory synaptogenesis (23); 
a similar mechanism in spinal cord can lead to behavioral 
hypersensitivity. Because gabapentin binds to a site upstream 
of the VWF-A domain of Cavα2δ1 (24), it is less likely that 
the inhibitory effects of gabapentin on EGF-LIKE–induced behav- 
oral hypersensitivity are mediated through direct blockage of 
TSP4 binding to Cavα2δ1. Instead, binding of small molecules 
such as gabapentin to Cavα2δ1 may cause conformational 
changes of the protein that may interfere with TSP4/Cavα2δ1 
interactions. This is supported by recent findings that TSP4 
binding to Cavα2δ1 can reduce gabapentin binding to Cavα2δ1, 
but this effect is diminished with mutations in the VWF-A 
domain of Cavα2δ1 (22).

We hypothesized that a peptide from the EGF-LIKE se- 
quence might interfere with EGF-LIKE/Cavα2δ1 interactions, 
thereby blocking TSP4/Cavα2δ1 pathway activation and attenu- 
ating behavioral hypersensitivity. To test this, we designed 
peptide EGFD355–369 and tested its effects in blocking be- 
havioral hypersensitivity induced by elevated TSP4 and/or 
Cavα2δ1. Intrathecal injection of this peptide can block tactile 
allodynia induced by intrathecal TSP4 injection in rats and 
Cavα2δ1 overexpression in transgenic mice without affecting 
baseline behavioral sensitivity in naïve animals. Therefore, 
peptide EGFD355–369 can block behavioral hypersensitivity 
induced by elevated TSP4 or Cavα2δ1 alone. Its anti-nociceptive 
effects are specific because neither a high-affinity binding pep- 
tide from the coiled-coil domain (data not shown) nor the 
scrambled control peptide has any functional effect in blocking
nociception. Because intrathecal injection of EGF-LIKE–containing proteins (TSP4, ND, and EGF-LIKE) in naïve animals is pronociceptive but that of EGF-LIKE linear peptides alone is not, our data suggest that the nociceptive effect of TSP4 may require multiple binding sites and an optimal protein interface upon its interactions with Cav$_{a_2\delta_1}$/H9251$_2$/H9254$_1$.

Potential mechanisms underlying TSP4/Cav$_{a_2\delta_1}$/H9251$_2$/H9254$_1$-induced pain transduction and drug actions

Bolus injection of peptide EGFD355–369 blocks Cav$_{a_2\delta_1}$/H9251$_2$/H9254$_1$-induced tactile allodynia, confirming the requirement of a basal level of TSP4 for the pronociceptive effects of elevated Cav$_{a_2\delta_1}/$H9251$_2$/H9254$_1$(12). Enhanced excitatory transmission and behavioral hypersensitivity induced by Cav$_{a_2\delta_1}/$H9251$_2$/H9254$_1$ overexpression in neuronal cells can be attenuated by gabapentin (20) through inhibiting Cav$_{a_2\delta_1}$ and voltage-gated calcium channel trafficking to presynaptic axon terminals of nerve-injured DRG neurons in the dorsal horn (25, 26). Future studies to explore whether peptide EGFD355–369 could modulate excitatory neurotransmission and reduce Cav$_{a_2\delta_1}$ trafficking to the presynaptic sites in dorsal spinal cord would shed some light on the mechanistic contribution of TSP4 to behavioral hypersensitivity associated with Cav$_{a_2\delta_1}$.

Conversely, the ability of gabapentin to inhibit TSP4-(12) or EGF-LIKE–induced central sensitization and behavioral hypersensitivity highlights a critical role of the TSP4/Cav$_{a_2\delta_1}$/H9251$_2$/H9254$_1$ pathway in mediating chronic pain states. Because gabapentin can block TSP-induced excitatory synapse formation (21, 23), dorsal horn neuron sensitization, and behavioral hypersensitivities (12), it is likely that activation of the TSP4/Cav$_{a_2\delta_1}$/H9251$_2$/H9254$_1$ pathway by EGF-LIKE contributes to aberrant excitatory synaptogenesis, central sensitization, and pain states. This is supported by our recent findings that trigeminal nerve injury causes increased expression of Cav$_{a_2\delta_1}$ and TSP4 in dorsal spinal cord that correlates with aberrant excitatory synaptogenesis and enhances presynaptic excitatory input and neuropathic pain states (14, 27). Our findings reveal that only TSP4 proteins containing EGF-LIKE are synaptogenic and pronociceptive, but NT+CC domain proteins lacking EGF-LIKE are not even though they have similar Cav$_{a_2\delta_1}$ binding affinity as full-length TSP4. Together, these data support that specific interactions between EGF-LIKE and Cav$_{a_2\delta_1}$/H9251$_2$/H9254$_1$, but not multidomain-binding
interactions between TSP4 and Ca$_{\alpha_2\delta_1}$, are critical in mediating synaptogenesis and behavioral hypersensitivity.

Our findings reveal that gabapentin and peptide EGFD355–369 can block excitatory synaptogenesis and behavioral hypersensitivity induced by EGF-LIKE without affecting basal level values, supporting that aberrant synapse formation induced by interactions of EGF-LIKE with Ca$_{\alpha_2\delta_1}$ contributes to behavioral hypersensitivity. Interestingly, both gabapentin and peptide EGFD355–369 have a rapid onset time (within 2 h) and short duration (<4 h) in blocking pain states. This time frame coincides with that of new excitatory synapse formation in vitro and in vivo. For example, new excitatory synapses can be assembled in vitro within 1–2 h of initial axodendritic contact (28, 29), which correlates with the time for new synaptic spine formation after high frequency stimulation (30–32). In vivo data indicate that activity-dependent synaptic stabilization and elimination are dynamic processes that can occur as rapidly as <30 min to 2 h poststimulation (33, 34). These rapidly assembled excitatory synapses are initiated by presynaptic remodeling through recruitment and stabilization of presynaptic packets containing calcium channel subunits (28). Thus, it is possible that binding of TSP4, or EGF-LIKE, proteins to Ca$_{\alpha_2\delta_1}$ promotes the assembly/recruitment of presynaptic protein precur-

**Synaptogenic and pronociceptive domains of TSP4**

sors and/or stabilization of presynaptic remodeling after nerve injury that allows a rapid initiation of new excitatory synapse formation. Supportive findings include that injury-induced CA$_{\alpha_2\delta_1}$ proteins are translocated from injured DRG neurons to their presynaptic terminals in dorsal spinal cord (5, 26) and play a role in axonal trafficking and presynaptic assembly (26, 35). This in turn can lead to increased presynaptic excitatory input into dorsal horn neurons (18, 19, 35) that can accelerate stimulation-dependent aberrant synapse formation (30–32). Gabapentin or peptide EGFD355–369 can bind to CA$_{\alpha_2\delta_1}$, likely induce conformational changes of target proteins, and prevent rapid aberrant synaptogenesis initiated by TSP4/CA$_{\alpha_2\delta_1}$ interactions, leading to pain state reversal. This is supported by our recent findings that early gabapentin treatment can prevent TSP4-induced excitatory synaptogenesis and behavioral hypersensitivity (21).

The transient effects of gabapentin and EGFD355–369 in reversing pain state may be due to the short half-life of these agents in vivo because gabapentin has a mean elimination half-life about 2 h in rats (36), and the half-life of peptides in rats can range from minutes to 2 h (37, 38). Modifications to improve the stability and pharmacokinetics of these agents may provide better therapeutic values. However, we cannot rule out the possibility that the effects of gabapentin and the peptide are independent from its binding to CA$_{\alpha_2\delta_1}$–TSP4 complexes. Detailed studies using mutational analyses across CA$_{\alpha_2\delta_1}$ and/or EGF-LIKE should provide further mechanistic insights. A recent study reports that gabapentin’s anti-nociceptive effects could be mediated by its selective inhibition of CA$_{\alpha_2\delta_1}$-bound NMDA receptors on the cell membrane surface (39). Because TSP4 and CA$_{\alpha_2\delta_1}$ also form complexes in spinal cord (12), it will be interesting to investigate whether TSP4 plays a contributory role to events associated with CA$_{\alpha_2\delta_1}$–NMDA receptor complex formation.

**Summary and conclusion**

In summary, our findings demonstrate that EGF-LIKE is the molecular determinant in mediating excitatory synaptogenesis and behavioral hypersensitivity and requires its interaction with CA$_{\alpha_2\delta_1}$. Blocking EGF-LIKE/CA$_{\alpha_2\delta_1}$ interaction can be an alternative approach in designing target-specific medications for neuropathic pain management.

**Experimental procedures**

**Construction of recombinant TSP4 truncated cDNA**

The recombinant truncated TSP4 constructs were prepared by the PCR-driven overlap extension technique (40) using full-length rat TSP4 cDNA (GenBank™ accession number X89963) in a pCEP-Pu vector as template (a gift from Dr. Frank Zaucke, University of Cologne). Segments of the TSP4 cDNA were amplified using two flanking master primers and internal primers that introduce the mutation for truncation and create internal primers CACGCGCTAGTCTCTGTCCG (forward), CTGGAACAGAGAGACTAGCGCGTG (reverse) and scrambled peptide CTGGAACAGAGAGACTAGCGCGTG (reverse) along spinal neuron dendrites (MAP2, blue). Puncta of colocalized synaptic marker immunoreactivity were quantified as synapse numbers. B, summarized synapse numbers in cocultures after each treatment. Data presented are the means from 13–17 neurons per group in each of three independent experiments with error bars representing 95% confidence interval. ***, p < 0.001 compared with control by repeated measures one-way ANOVA with a Dunnett’s post hoc test.

Figure 7. Synaptogenic effects of the TSP4 EGF-LIKE domain protein were blocked by peptide EGFD355–369. Synaptogenesis analysis was performed in cocultures of DRG and spinal cord neurons after treatment for 4 days with PBS (CTL) or 20 nm EGF-LIKE proteins in the absence or presence of an equal molar concentration of scrambled control peptide or peptide EGFD355–369 in multiple-well plates of independent experiments. A, representative confocal images showing immunoreactivities to antibodies of synaptic markers (Vglut2, red; PSD95, green) along spinal neuron dendrites (MAP2, blue). Puncta of colocalized synaptic marker immunoreactivity were quantified as synapse numbers. B, summarized synapse numbers in cocultures after each treatment. Data presented are the means from 13–17 neurons per group in each of three independent experiments with error bars representing 95% confidence interval. ***, p < 0.001 compared with control by repeated measures one-way ANOVA with a Dunnett’s post hoc test.

**Abbreviations**

A, scrambled peptide; B, Peptide EGFD355–369; CTTATCATGTCTGGATCCGGC (forward), CTGGAACAGAGAGACTAGCGCGTG (reverse) and scrambled peptide CTGGAACAGAGAGACTAGCGCGTG (reverse) along spinal neuron dendrites (MAP2, blue). Puncta of colocalized synaptic marker immunoreactivity were quantified as synapse numbers. B, summarized synapse numbers in cocultures after each treatment. Data presented are the means from 13–17 neurons per group in each of three independent experiments with error bars representing 95% confidence interval. ***, p < 0.001 compared with control by repeated measures one-way ANOVA with a Dunnett’s post hoc test.
Synaptogenic and pronociceptive domains of TSP4

The recombinant rat TSP4 cDNA (GenBank accession number X89963) with a His<sub>6</sub> tag at the N-terminal was transfected into human embryonic kidney cell line 293-EBNA (Invitrogen) using the calcium phosphate transfection method. The transfected cells were selected with 0.5 µg/ml puromycin and grown to confluence. Secretion of the full-length TSP4-His and truncated TSP4-His proteins into Dulbecco’s modified Eagle’s medium (DMEM)/F-12 medium (Mediatech, Manassas, VA) was confirmed by Western blotting using anti-penta-His monoclonal antibodies (Qiagen, Valencia, CA). The recombinant TSP4-His proteins were purified using a nickel-nitritotriacetic acid column based on the manufacturer’s instructions (Invitrogen), concentrated with an Amicon Ultra-4 centrifugal filter unit based on the cutoff molecular weight (Millipore, Billerica, MA), verified using Western blot analysis, aliquoted, and stored at −80 °C until use.

**Western blot analysis**

Protein samples were denatured in the presence of DTT, heated to 70 °C for 10 min, and then loaded onto a 4–12% NuPAGE Bis-Tris gel (Invitrogen) for gel electrophoresis. Proteins were transferred onto polyvinylidene difluoride membrane and blocked with 5% skim milk powder in PBS-T (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na<sub>2</sub>HPO<sub>4</sub>, 1.4 mM KH<sub>2</sub>PO<sub>4</sub>, 0.1% Tween 20, pH 7.4) at room temperature. The immunoblot was probed with anti-penta-His monoclonal antibodies (Qiagen; 1:1000) overnight at 4 °C and then incubated with secondary anti-mouse IgG antibody conjugated with horseradish peroxide (HRP) (Cell Signaling Technology; 1:2000) for 1 h at room temperature followed by enhanced chemiluminescence detection of the protein–antibody complexes in an Eastman Kodak Co. image station (2000MM).

**Purification of FLAG-Ca<sub>α</sub>2<sub>δ</sub>1**

FLAG-Ca<sub>α</sub>2<sub>δ</sub>1 cDNA was transiently transfected into HEK 293 cells using Lipofectamine 2000 (Invitrogen). Transfected cells were washed twice with PBS and then extracted in protein extraction buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.1% Triton X-100, pH 7.4) 2–3 days after the transfection. The cell lysate was incubated on ice for 15 min followed by centrifugation at 13,000 × g for 20 min at 4 °C. The supernatant was incubated with anti-FLAG M2 agarose affinity resin (Sigma-Aldrich) on a rotating mixer for 2 h at 4 °C and then washed three times with protein extraction buffer. FLAG-Ca<sub>α</sub>2<sub>δ</sub>1 was eluted in elution buffer (0.1 M glycine, pH 3.5) and stored at −20 °C for future use.

**ELISA-based binding assay**

The reagents for solid-phase binding were from Invitrogen (catalog number CNB0011). Recombinant TSP4 proteins were immobilized onto a 96-well polystyrene plate (Thermo Fisher Scientific) overnight at 4 °C in coating buffer A (10 mM phosphate buffer, 0.1% azide, pH 7.4). All further incubations were carried out at room temperature for 1 h, and proteins or antibodies were diluted in assay buffer containing bovine serum albumin (BSA). After blocking, the plates were incubated with affinity-purified FLAG-Ca<sub>α</sub>2<sub>δ</sub>1 for 1 h, washed, and then incubated with mouse monoclonal anti-FLAG antibodies (1:1000; Sigma-Aldrich) followed by HRP-conjugated secondary antibodies. The bound FLAG-Ca<sub>α</sub>2<sub>δ</sub>1 complexes were detected by measuring a color reaction (yellow product) at 450 nm after adding tetramethylbenzidine for 15 min followed by adding sulfuric acid to stop the reaction.

**SPOT peptide array and far-Western blotting**

Peptide arrays containing overlapping peptides (15-mers; overlapping by 12 amino acids) covering the entire length of rat TSP4 protein were synthesized and immobilized onto a cellulose membrane (Sigma-Aldrich custom SPOT service). The peptide array was rinsed with methanol for 5 min, washed with TBS-T (50 mM Tris, 137 mM NaCl, 2.7 mM KCl, 0.05% Tween 20, pH 8.0), and blocked with 5% dry milk in TBS-T for 1 h at room temperature. Plasma membranes from tsA-201 cells stably expressing Ca<sub>2.2</sub>e (Δ24a,31a), Ca<sub>β</sub><sub>1d</sub>, and Ca<sub>α</sub>2<sub>δ</sub>1 were collected in Tris buffer (5 mM Tris/HCl, 5 mM EDTA, pH 7.4, containing PMSF, leupeptin, and pepstatin A), incubated on ice for 15 min, sonicated, and then centrifuged at 1000 × g for 10 min. The supernatant was collected and centrifuged at 50,000 × g for 30 min at 4 °C. The resulting pellet was resuspended in Tris buffer (0.1 µg/ml) and incubated with the peptide array in 5% dry milk for 1 h at room temperature. Binding of Ca<sub>α</sub>2<sub>δ</sub>1 to the peptide array was detected by incubating the peptide array for 2 h at room temperature with primary antibodies against Ca<sub>α</sub>2<sub>δ</sub>1 (1:1000; mouse; Sigma-Aldrich) and then HRP-conjugated secondary antibodies against mouse IgG.
for 1 h at room temperature (1:2000; Cell Signaling Technology) followed by enhanced chemiluminescence detection.

**Peptides**

The following peptides were synthesized and verified by MS and HPLC analysis by Genscript (Piscataway, NJ): EGF-LIKE domain peptide of TSP4 (PGVRCNLAPGFRCD) (EGFD355–369; GenBank accession number CA62002) and its scrambled control peptide (GLAFVNCPRRDTGCP). The lyophilized peptides were dissolved in sterile water before use.

**Animals**

Male adult Harlan Sprague-Dawley rats (<150 g) were from Harlan Sprague-Dawley Industries (Indianapolis, IN). Adult male and female mice (20–30 g) with 129sv background were from Charles River Laboratories (Wilmington, MA). They were bred internally to obtain pregnant females for spinal cord cell culture. The Cav2.1 transgenic mice were generated and characterized as described in our previous publication (20). Briefly, a neuronal specific thy-1 promoter (44) was used to drive overexpression of the mouse brain Cav2.1αδ2 cDNA (GenBank accession number U73484) in the transgenic mice. These genetically modified mice were fertile and showed normal growth, grooming, social interactions, and feeding. They were backcrossed to the 129sv background for over 10 generations before use. Mouse genotyping was performed by TransnetYX, Inc. (Cordova, TN). All animals were housed in separate cages and exposed to a 12-h light/dark cycle and fed ad libitum. All animal care and experiments were performed according to protocols approved by the Institutional Animal Care Committees of the University of California, Irvine.

**Tactile alldynia**

The animals were placed in Plexiglass chambers on a wire mesh–bottomed cage for acclimatization (at least 60 min). von Frey filaments (Stoelting, Wood Dale, IL) were used to determine the 50% paw withdrawal threshold (PWT) using the up-down method of Dixon (45). A series of von Frey filaments were applied to both plantar surfaces of the hind paws, starting with a buckling weight of 2.0 or 0.41 g for a rat or mouse, respectively, with sufficient force to cause the filament to buckle. A positive response was defined as a rapid withdrawal and/or licking of the paw upon application of the stimulus, which prompted the use of the next weaker filament. Absence of a paw withdrawal response after 5 s prompted the use of the next filament of increasing weight. This paradigm was continued until four more measurements have been made after the initial change of the behavioral response or until five consecutive negative (assigned a score of 15 g for rats or 2 g for mice) or four consecutive positive (assigned a score of 0.25 g for rats or 0.01 g for mice) responses had occurred. The resulting scores of six (starting from the one before the first change in response) were used to calculate the 50% response threshold as described previously (3).

**Thermal hyperalgesia (Hargreaves method)**

The animals were placed in Plexiglass chambers on a glass panel that was maintained at 30 °C for acclimatization (at least 60 min). A heat stimulus projecting through a small aperture below the glass panel from a high intensity light bulb was applied to both plantar surfaces of the hind paws. When the animals moved their paw away from the thermal stimulus, the light beam was shut off automatically. The length of time between the start of the light beam and the hind paw withdrawal was defined as the paw withdrawal latency. A cutoff time of 20 s was used to avoid tissue damage to the hind paw.

**Cell culture**

A DRG/spinal cord primary neuron coculture system derived from published protocols (46–49) with minor modifications (26, 50–53) was used for in vitro synaptogenesis analysis. Briefly, at least six E14–E19 mouse embryos (for spinal cord neurons) and three adult mice (for DRG neurons) were used for each multiwell culture plate in independent experiments. Spinal cord neurons were dissociated with 0.25% trypsin in DMEM, plated onto 0.1 mg/ml poly-d-lysine– and 0.04 mg/ml laminin-coated glass coverslips, and grown in DMEM supplemented with 10% horse serum and 10% fetal bovine serum. After 24 h, the media were replaced with neurobasal medium supplemented with B27 supplement (NB/B27) to allow spinal cord neuron maturation and neurite sprouting for 3 days. Adult DRG (T9–L5) were harvested after hydraulic extrusion of spinal cord and laminectomy from Advillin-Cre/Rosa-tdTmato mice, which expressed red fluorescent proteins driven by the Advillin promoter in about 90% of DRG neurons (54, 55). Neurons were dissociated in DMEM containing 1.25 mg/ml collagenase (Sigma) and added to the spinal cord neuron cultures at the time of culture media change at day 4. The cocultures were maintained in NB/B27 supplement with 100 nM uridine and 20 nM 5-fluorodeoxyuridine to control nonneuronal cell proliferation. The culture cell treatments started about 2–3 days after DRG cell addition.

**Immunohistochemistry**

Excitatory synapse numbers in cultured cells were analyzed as described previously (12, 21, 51). Because a single investigator performed all the immunohistochemical experiments, data analyses were not double blinded. Briefly, after heat-based antigen retrieval as described previously, cell samples were stained with primary antibodies against vesicular glutamate transporter 2 (VGlut2; guinea pig; Synaptic Systems), postsynaptic density protein 95 (PSD95; rabbit; Thermo Fisher Scientific), and microtubule-associated protein 2 (MAP2) (chicken; Abcam) at 4 °C overnight. Our laboratory and others have done validation of these antibodies as reported previously (12). After washing, samples were incubated with species-specific secondary antibodies conjugated to unique fluorophores for 2 h at room temperature and washed again. Fluorescence images were acquired with a confocal microscope (Zeiss LSM700, University of California Irvine Optical Biology Core) in 0.3-μm-thick Z stacks. DRG axons could be traced by tdTomato red fluorescence. Because VGlut2 immunoreactivity is mainly in presynaptic vesicles, but not axons, and tdTomato fluorescence is mainly expressed along DRG neuron axons, but not in presynaptic vesicles, it was highly likely that VGlut2 immunoreactivity detected within the dendritic spinelike structure along

**Synaptogenic and pronociceptive domains of TSP4**

Animals were placed in Plexiglass chambers on a wire mesh–bottomed cage for acclimatization (at least 60 min). A heat stimulus projecting through a small aperture below the glass panel from a high intensity light bulb was applied to both plantar surfaces of the hind paws. When the animals moved their paw away from the thermal stimulus, the light beam was shut off automatically. The length of time between the start of the light beam and the hind paw withdrawal was defined as the paw withdrawal latency. A cutoff time of 20 s was used to avoid tissue damage to the hind paw.

**Cell culture**

A DRG/spinal cord primary neuron coculture system derived from published protocols (46–49) with minor modifications (26, 50–53) was used for in vitro synaptogenesis analysis. Briefly, at least six E14–E19 mouse embryos (for spinal cord neurons) and three adult mice (for DRG neurons) were used for each multiwell culture plate in independent experiments. Spinal cord neurons were dissociated with 0.25% trypsin in DMEM, plated onto 0.1 mg/ml poly-d-lysine– and 0.04 mg/ml laminin-coated glass coverslips, and grown in DMEM supplemented with 10% horse serum and 10% fetal bovine serum. After 24 h, the media were replaced with neurobasal medium supplemented with B27 supplement (NB/B27) to allow spinal cord neuron maturation and neurite sprouting for 3 days. Adult DRG (T9–L5) were harvested after hydraulic extrusion of spinal cord and laminectomy from Advillin-Cre/Rosa-tdTmato mice, which expressed red fluorescent proteins driven by the Advillin promoter in about 90% of DRG neurons (54, 55). Neurons were dissociated in DMEM containing 1.25 mg/ml collagenase (Sigma) and added to the spinal cord neuron cultures at the time of culture media change at day 4. The cocultures were maintained in NB/B27 supplement with 100 nM uridine and 20 nM 5-fluorodeoxyuridine to control nonneuronal cell proliferation. The culture cell treatments started about 2–3 days after DRG cell addition.
MAP2 immunoreactivity was from VGlut2 immunostaining and not from tdTomato fluorescence (21). This allowed measurement of excitatory synapses between sensory axons and individual dendrites of each spinal cord neuron with overlapping VGlut2, PSD95, and MAP2 immunoreactivity along with or surrounded by red DRG axons. Corrections for variations in dendrite size and numbers among individual spinal cord neurons were done by calculating synapse count/μm² area of MAP2-immunoreactive dendrites of that neuron. Data analyses were performed on merged seven consecutive Z stacks with the best signal using Volocity 6.0 (PerkinElmer Life Sciences).

Author contributions—J. F. P. data curation; J. F. P., Y. P. Y., and N. G. formal analysis; J. F. P., Y. P. Y., N. G., and V. N. T. investigation; J. F. P. writing–original draft; Z. D. L. conceptualization; Z. D. L. supervision; Z. D. L. funding acquisition; Z. D. L. validation; Z. D. L. writing–review and editing.

Acknowledgments—We thank Dr. Frank Zaucke (University of Cologne) for the tsA-201 stable cell lines.

References

1. Woolf, C. J., and Mannion, R. J. (1999) Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 353, 1959–1964 CrossRef Medline
2. Costigan, M., Scholz, J., and Woolf, C. J. (2009) Neuropathic pain: a maladaptive response of the nervous system to damage. Annu. Rev. Neurosci. 32, 1–32 CrossRef Medline
3. Luo, Z. D., Chaplin, S. R., Higuera, E. S., Sorkin, L. S., Stauderman, K. A., Williams, M. E., and Yakshe, T. L. (2001) Upregulation of dorsal root ganglion α6-δ calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J. Neurosci. 21, 1868–1875 CrossRef Medline
4. Luo, Z. D., Calcutt, N. A., Higuera, E. S., Valder, C. R., Song, Y. H., Svensson, C. I., and Myers, R. R. (2002) Injury type-specific calcium channel α6-δ subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J. Pharmacol. Exp. Ther. 303, 1199–1205 CrossRef Medline
5. Li, C. Y., Song, Y. H., Higuera, E. S., and Luo, Z. D. (2004) Spinal dorsal horn calcium channel α6-δ subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J. Neurosci. 24, 8494–8499 CrossRef Medline
6. Kim, D. S., Figueroa, K. W., Li, K. W., Boroujerdi, A., Yolo, T., and Luo, Z. D. (2009) Profiling of dynamically changed gene expression in dorsal root ganglia post peripheral nerve injury and a critical role of injury-induced glial fibillary acidic protein in maintenance of pain behaviors [corrected]. Pain 143, 114–122 CrossRef Medline
7. Valder, C. R., Liu, J. J., Song, Y. H., and Luo, Z. D. (2003) Coupling gene chip analyses and rat genetic variances in identifying potential target genes that may contribute to neuropathic allodynia development. J. Neurochem. 87, 560–573 CrossRef Medline
8. Wang, H., Sun, H., Della Penna, K., Benz, R. J., Xu, J., Gerhold, D. L., Holder, D. L., and Koblan, K. S. (2002) Chronic neuropathic pain is accompanied by global changes in gene expression and shares pathology with neurodegenerative diseases. Neuroscience 114, 529–546 CrossRef Medline
9. Kim, D. S., Li, K. W., Boroujerdi, A., Peter Yu, Y., Zhou, C. Y., Deng, P., Park, J., Zhang, X., Lee, J., Corpse, M., Sharp, K., Steward, O., Erogul, C., Barres, B., Zauke, F., et al. (2012) Thrombospondin-4 contributes to spinal sensitization and neuropathic pain states. J. Neurosci. 32, 8977–8987 CrossRef Medline
10. Adams, J. C., and Lawler, J. (2004) The thrombospondins. Int. J. Biochem. Cell Biol. 36, 961–968 CrossRef Medline
11. Bornstein, P. (2001) Thrombospondins as matricellular modulators of cell function. J. Clin. Investig. 107, 929–934 CrossRef Medline
12. Park, J., Yu, Y. P., Zhou, C. Y., Li, K. W., Wang, D., Chang, E., Kim, D. S., Yu, B., Zhang, X., Gong, N., Sharp, K., Steward, O., Vitko, I., Perez-Reyes, E., Eroglu, C., et al. (2016) Central mechanisms mediating thrombospondin-4-induced pain states. J. Biol. Chem. 291, 13335–13348 CrossRef Medline
13. Zeng, J., Kim, D., Li, K. W., Sharp, K., Steward, O., Zauke, F., and Luo, Z. D. (2013) Thrombospondin-4 contributes to spinal cord injury-induced changes in nociception. Eur. J. Pain 17, 1458–1464 CrossRef Medline
14. Li, K. W., Kim, D. S., Zauke, F., and Luo, Z. D. (2014) Trigeminal nerve injury-induced thrombospondin-4 up-regulation contributes to orofacial neuropathic pain states in a rat model. Eur. J. Pain 18, 489–495 CrossRef Medline
15. Gee, N. S., Brown, J. P., Dissanyake, V. U., Offord, J., Thurlow, R., and Woodruff, G. N. (1996) The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α6 subunit of a calcium channel. J. Biol. Chem. 271, 5768–5776 CrossRef Medline
16. Marais, E., Klugbauer, N., and Hofmann, F. (2001) Calcium channel α6δ subunits-structure and gabapentin binding. Mol. Pharmacol. 59, 1243–1248 CrossRef Medline
17. Nguyen, D., Deng, P., Matthews, E. A., Kim, D. S., Feng, G., Dickenson, A. H., Xu, Z. C., and Luo, Z. D. (2009) Enhanced pre-synaptic glutamate release in deep-dorsal horn contributes to calcium channel α2-δ-1 protein-mediated spinal sensitization and behavioral hypersensitivity. Mol. Pain 5, 6 CrossRef Medline
18. Zhou, C., and Luo, Z. D. (2014) Electrophysiological characterization of spinal neuron sensitization by elevated calcium channel α2-δ-1 subunit protein. Eur. J. Pain 18, 649–658 CrossRef Medline
19. Zhou, C., and Luo, Z. D. (2015) Neuronal injury-induced calcium channel α2-δ-1 protein dysregulation leads to increased pre-synaptic excitatory input into deep dorsal horn neurons and neuropathic allodynia. Eur. J. Pain 19, 1267–1276 CrossRef Medline
20. Li, C. Y., Zhang, X. L., Matthews, E. A., Li, K. W., Kurwa, A., Boroujerdi, A., Gross, J., Gold, M. S., Dickenson, A. H., Feng, G., and Luo, Z. D. (2006) Calcium channel α2β1 subunit mediates spinal hyperexcitability in pain modulation. Pain 125, 20–34 CrossRef Medline
21. Yu, Y. P., Gong, N., Kweon, T. D., Vo, B., and Luo, Z. D. (2018) Gabapentin prevents synaptogenesis between sensory and spinal cord neurons induced by thrombospondin-4 acting on pre-synaptic Ca2+ α6δ subunits and involving T-type Ca2+ channels. Br. J. Pharmacol. 175, 2348–2361 CrossRef Medline
22. Lana, B., Page, K. M., Kadurin, I., Ho, S., Nieto-Rostro, M., and Dolphin, A. C. (2016) Thrombospondin-4 reduces binding affinity of [3H]-gabapentin to calcium channel α6δ-1-subunit but does not interact with α6δ-1 on the cell-surface when co-expressed. Sci. Rep. 6, 24531 CrossRef Medline
23. Erogul, C., Allen, N. J., Susman, M. W., O’Rourke, N. A., Park, C. Y., Ozkan, E., Chakraborty, C., Mulinyawe, S. B., Anns, D. S., Huberman, A. D., Green, E. M., Lawler, J., Dolmetsch, R., Garcia, K. C., Smith, S. J., Luo, Z. D., et al. (2009) Gabapentin receptor α2δ-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 139, 380–392 CrossRef Medline
24. Wang, M., Offord, J., Oxender, D. L., and Su, T. Z. (1999) Structural requirement of the calcium-channel subunit α2δ for gabapentin binding. Biochem. J. 342, 313–320 Medline
25. Hendrich, J., Van Minh, A. T., Heblich, F., Nieto-Rostro, M., Watschinger, K., Stiessnig, J., Wratten, J., Davies, A., and Dolphin, A. C. (2008) Pharmacological disruption of calcium channel trafficking by the α2δ ligand gabapentin. Proc. Natl. Acad. Sci. U.S.A. 105, 3628–3633 CrossRef Medline
26. Bauer, C. S., Nieto-Rostro, M., Rahman, W., Tran-Van-Minh, A., Ferron, L., Douglas, L., Kadurin, I., Sri Ranjan, Y., Fernandez-Alacid, L., Millar, E., Eroglu, C., et al. (2016) Thrombospondin-4 reduces binding affinity of [3H]-gabapentin to calcium channel α6δ-1-subunit but does not interact with α6δ-1 on the cell-surface when co-expressed. Sci. Rep. 6, 24531 CrossRef Medline

Synaptogenic and pronociceptive domains of TSP4

16462 J. Biol. Chem. (2018) 293(42) 16453–16463

ASBMB
27. Li, K. W., Yu, Y. P., Zhou, C., Kim, D. S., Lin, B., Sharp, K., Steward, O., and Luo, Z. D. (2014) Calcium channel α2δ1 proteins mediate trigeminal neuropathic pain states associated with aberrant excitatory synaptogenesis. J. Biol. Chem. 289, 7025–7037 CrossRef Medline

28. Ahmari, S. E., Buchanan, J., and Smith, S. J. (2000) Assembly of presynaptic active zones from cytoplasmic transport packets. Nat. Neurosci. 3, 445–451 CrossRef Medline

29. Friedman, H. V., Bresler, T., Garner, C. C., and Ziv, N. E. (2000) Assembly of presynaptic active zones from cytoplasmic transport packets. Nat. Neurosci. 3, 445–451 CrossRef Medline

30. Engert, F., and Bonhoeffer, T. (1999) Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature 399, 66–70 CrossRef Medline

31. Toni, N., Buchs, P. A., Nikonenko, I., Bron, C. R., and Muller, D. (1999) Visualizing synapse formation of multiple spine synapses between a single axon terminal and a dendrite. Nature 402, 421–425 CrossRef Medline

32. Hoppa, M. B., Lana, B., Margas, W., Dolphin, A. C., and Ryan, T. A. (2012) Synaptic molecule recruitment. J. Neurosci. 26, 3594–3603 CrossRef Medline

33. Maletic-Savatic, M., Malinow, R., and Svoboda, K. (1999) Rapid dendritic morphogenesis in CA1 hippocampal dendrites induced by synaptic activity. Science 283, 1923–1927 CrossRef Medline

34. Lin, Y., McDonough, S. L., and Lipscombe, D. (2004) Alternative splicing in the voltage-sensing region of N-type CaV2.2 channels modulates channel kinetics. J. Neurophysiol. 92, 2820–2830 CrossRef Medline

35. Vidal, M., Morris, R., Grosfeld, F., and Spanopoulou, E. (1990) Tissue-specific control elements of the Thy-1 gene. EMBO J. 9, 833–840 CrossRef Medline

36. Dixon, W. J. (1980) Efficient analysis of experimental observations. Annu. Rev. Pharmacol. Toxicol. 20, 441–462 CrossRef Medline

37. Albuquerque, C., Joseph, D. J., Choudhury, P., and MacDermott, A. B. (2009) Dissection, plating, and maintenance of dorsal root ganglion neurons for monoculture and for coculture with dorsal horn neurons. Cold Spring Harb. Protoc. 2009, pdb.prot5275 CrossRef Medline

38. Albuquerque, C., Joseph, D. J., Choudhury, P., and MacDermott, A. B. (2009) Dissection, plating, and maintenance of dorsal horn neuron cultures. Cold Spring Harb. Protoc. 2009, pdb.prot5274 CrossRef Medline

39. Milligan, E. D., Langer, S. J., Sloane, E. M., He, L., Wieseler-Frank, J., Al Banchaabouchi, M., et al. (2009) Dissection, plating, and maintenance of dorsal root ganglion neurons for monoculture and for coculture with dorsal horn neurons. Cold Spring Harb. Protoc. 2009, pdb.prot5275 CrossRef Medline

40. Narouz-Ott, L., Maurer, P., Nitsche, D. P., Smyth, N., and Paulsson, M. (2000) Thrombospondin-4 binds specifically to both collagenous and non-collagenous extracellular matrix proteins via its C-terminal domains. J. Biol. Chem. 275, 37110–37117 CrossRef Medline

41. Kohfeldt, E., Maurer, P., Vannahme, C., and Timpl, R. (1997) Properties of the extracellular calcium binding module of the proteoglycan testican. FEBS Lett. 414, 557–561 CrossRef Medline

42. Varon, S., and Raiborn, C. (1971) Excitability and conduction in neurons of rat hypothalamus. J. Neurosci. 23, 198–206 CrossRef Medline

43. Varon, S., and Raiborn, C. (1971) Excitability and conduction in neurons of rat hypothalamus. J. Neurosci. 23, 198–206 CrossRef Medline

44. Burkey, T. H., Hingtgen, C. M., and Vasko, M. R. (2004) Isolation and culture of adult rat dorsal root ganglia neurons. FEBS Lett. 569, 26–32 CrossRef Medline

45. Albuquerque, C., Joseph, D. J., Choudhury, P., and MacDermott, A. B. (2009) Dissection, plating, and maintenance of dorsal root ganglion neurons for monoculture and for coculture with dorsal horn neurons. Cold Spring Harb. Protoc. 2009, pdb.prot5275 CrossRef Medline

46. Burkey, T. H., Hingtgen, C. M., and Vasko, M. R. (2004) Isolation and culture of adult rat dorsal root ganglia neurons. J. Neurosci. Res. 23, 198–206 CrossRef Medline

47. Albuquerque, C., Joseph, D. J., Choudhury, P., and MacDermott, A. B. (2009) Dissection, plating, and maintenance of dorsal horn neuron cultures. Cold Spring Harb. Protoc. 2009, pdb.prot5274 CrossRef Medline

48. Topol, D., Leprince, P., Schoenen, J., and Moonen, G. (1989) Purification and culture of adult rat dorsal root ganglia neurons. J. Neurosci. Res. 23, 198–206 CrossRef Medline

49. Topol, D., Leprince, P., Schoenen, J., and Moonen, G. (1989) Purification and culture of adult rat dorsal root ganglia neurons. J. Neurosci. Res. 23, 198–206 CrossRef Medline

50. Moreira, P., Perlas, E., and Heppenstall, P. A. (2011) Generation and characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant. Peptides 32, 660–667 CrossRef Medline

51. Moreira, P., Perlas, E., and Heppenstall, P. A. (2011) Generation and characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant. Peptides 32, 660–667 CrossRef Medline

52. Topol, D., Leprince, P., Schoenen, J., and Moonen, G. (1989) Purification and culture of adult rat dorsal root ganglia neurons. J. Neurosci. Res. 23, 198–206 CrossRef Medline

53. Topol, D., Leprince, P., Schoenen, J., and Moonen, G. (1989) Purification and culture of adult rat dorsal root ganglia neurons. J. Neurosci. Res. 23, 198–206 CrossRef Medline

54. Topol, D., Leprince, P., Schoenen, J., and Moonen, G. (1989) Purification and culture of adult rat dorsal root ganglia neurons. J. Neurosci. Res. 23, 198–206 CrossRef Medline

55. Topol, D., Leprince, P., Schoenen, J., and Moonen, G. (1989) Purification and culture of adult rat dorsal root ganglia neurons. J. Neurosci. Res. 23, 198–206 CrossRef Medline

56. Topol, D., Leprince, P., Schoenen, J., and Moonen, G. (1989) Purification and culture of adult rat dorsal root ganglia neurons. J. Neurosci. Res. 23, 198–206 CrossRef Medline

57. Topol, D., Leprince, P., Schoenen, J., and Moonen, G. (1989) Purification and culture of adult rat dorsal root ganglia neurons. J. Neurosci. Res. 23, 198–206 CrossRef Medline